Almirall
As of the edition of 20 October 2026, Almirall runs 33 drugs, 24 of them marketed; it is on route A at 0 targets and on route B at 11 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 24 |
| Active | 4 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 33 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluorouracil | none listed | 2 |
| Diclofenac | none listed | 7 |
| Calcipotriene | none listed | 1 |
| Dimethyl fumarate | none listed | 0 |
| Rivastigmine | none listed | 4 |
| Dapsone | none listed | 0 |
| Betamethasone | none listed | 6 |
| Erythromycin | none listed | 0 |
| Lebrikizumab | Ends 2036 (computed from the first US licence) | 1 |
| Tazarotene | none listed | 6 |
| Eflornithine | none listed | 3 |
| Tildrakizumab | Ends 2030 (computed from the first US licence) | 1 |
| Azelaic acid | none listed | 0 |
| Tirbanibulin | Ends 2038 (patent) | 1 |
| Retapamulin | Ends 2027 (patent) | 0 |
| Miconazole | none listed | 0 |
| Ciclopirox | none listed | 0 |
| Sarecycline | Ends 2033 (patent) | 0 |
| Almotriptan | none listed | 6 |
| Sodium lauryl sulfate | none listed | 0 |
| Flurandrenolide | none listed | 0 |
| Paraffin | none listed | 0 |
| Pidotimod | none listed | 0 |
| Tacalcitol | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 11 targets.
All 11 rows on route A or B
In the product11 company-target rows on route A or B; 8 are not shown here, and no score is.
See all 11 targets where Almirall needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 28 trials led
- Cancer: 11 trials led
- Immune system: 5 trials led